Clinical trials: Muscle-invasive Bladder Cancer
Non-muscle Invasive Bladder Cancer
A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer
The purpose of this study is to learn about the safety and effects of the study medicine (sasanlimab) in people with non-muscle invasive bladder cancer.
- Trial name
- CREST (NCT04165317)
- Testing
- PF-06801591, Bacillus Calmette-Guerin
- Where
- 196 sites in United States, Australia and 12 more
- Volunteers
- 1,068 people
- Sponsor
- Pfizer
Bladder Cancer, Urothelial Carcinoma
18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy
This research study is studying a positron emission tomography (PET) agent called 18F-fluciclovine to evaluate how well 18F-fluciclovine-PET scans determine the extent of muscle invasive bladder cancer (as compared to regular CT…
- Trial name
- NCT04018053
- Testing
- 18F-fluciclovine, PET/CT
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Brigham and Women's Hospital
Urinary Bladder Neoplasms
Safety and Efficacy Study of MAGE-A3 + AS-15 in Patients With Muscle-invasive Bladder Cancer After Cystectomy
The purpose of this clinical trial was to demonstrate the benefit of the immunotherapeutic product recMAGE-A3 + AS-15 given to patients with bladder cancer after removal of the bladder.
- Trial name
- MAGNOLIA (NCT01435356)
- Testing
- recMAGE-A3 + AS15 ASCI
- Where
- 50 sites in Czechia, France and 8 more
- Volunteers
- 83 people
- Sponsor
- European Association of Urology Research Foundation
Bladder Cancer
Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer
The purpose of this study is to find out if standard chemotherapy (gemcitabine and cisplatin) given on a dose-dense treatment schedule (with less time between treatments) can help shrink the tumor better than standard…
- Trial name
- NCT01589094
- Testing
- Gemcitabine and Cisplatin (DD GC)
- Where
- 8 sites in United States
- Volunteers
- 51 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Bladder Cancer
S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer
The primary focus of this study is to see if looking at tumor biomarkers using a program called coexpression extrapolation or "COXEN" may predict a patient's response to chemotherapy before surgery.
- Trial name
- COXEN (NCT02177695)
- Testing
- Gemcitabine, Cisplatin, Methotrexate
- Where
- 566 sites in United States
- Volunteers
- 237 people
- Sponsor
- SWOG Cancer Research Network
Bladder Cancer
Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer
The purposes of this study are to: find out whether participants' cancer returns or gets worse while they are taking lenalidomide and Bacille Calmette-Guerrin (BCG); evaluate the safety and tolerability of the combination of…
- Trial name
- NCT01373294
- Testing
- Bacille Calmette-Guerrin (BCG), Lenalidomide
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Bladder Cancer, Urothelial Carcinoma
Evaluation of NanoDoce® in Participants With Urothelial Carcinoma
This is a clinical trial studying the administration of NanoDoce as a direct injection to the bladder wall immediately after tumor resection and as an intravesical instillation.
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Urinary Bladder Neoplasm, Urinary Bladder Cancer
- Trial name
- NCT03636256
- Testing
- NanoDoce (direct injection), NanoDoce (intravesical instillation) - Visit 2 Instillation, Institutional Standard of Care
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- NanOlogy, LLC
Recurrent Bladder Carcinoma, Stage 0a Bladder Urothelial Carcinoma
Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer
The purpose of this study is to evaluate the efficacy (the effect of drug on tumor) and the tolerability (the effect of drug on the body) of pembrolizumab, when given as a single agent in patients with bladder tumors.
- Conditions
- Recurrent Bladder Carcinoma, Stage 0a Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Cancer
- Trial name
- NCT02808143
- Testing
- BCG Solution, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Northwestern University
Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma
Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)
This phase II trial studies the effect of avelumab, gemcitabine and carboplatin before surgery compared with surgery alone in treating patients with muscle invasive bladder or upper urinary tract cancer who are not able to…
- Conditions
- Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8
- Trial name
- NCT04871529
- Testing
- Therapeutic Conventional Surgery, Avelumab, Gemcitabine Hydrochloride
- Where
- 92 sites in United States
- Volunteers
- 6 people
- Sponsor
- SWOG Cancer Research Network
Bladder Cancer, Non-Muscle-Invasive Urothelial Carcinoma
BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder
The purpose of this study is to study the activity and effects of BGJ398 on bladder cancer tumors that are confined to the lining of the bladder.
- Trial name
- NCT02657486
- Testing
- BGJ398
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Muscle Invasive Bladder Cancer, High Risk Urothelial Carcinoma of the Upper Urinary Tracts
Dose Dense MVAC for Muscle Invasive Bladder Cancer
Standard treatment for early stage bladder cancer is chemotherapy with methotrexate (M), vinblastine (V), adriamycin (A), and cisplatin (C) followed by surgical removal of any remaining cancer and the bladder with the intent of…
- Trial name
- NCT01031420
- Testing
- single arm dose dense MVAC
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Fox Chase Cancer Center
Bladder Cancer, Urothelial Carcinoma
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
This Phase 3, multinational, single-arm study was designed to evaluate the efficacy and safety of UGN-102 as primary chemoablative therapy in patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer…
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
- Trial name
- ENVISION (NCT05243550)
- Testing
- UGN-102
- Where
- 65 sites in United States, Austria and 8 more
- Volunteers
- 240 people
- Sponsor
- UroGen Pharma Ltd.
Non-muscle Invasive Bladder Cancer (NMIBC)
Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC
This study, BC-819-18-204, is a Phase 2, open-label, monotherapy, single-arm, multicenter clinical trial of BC-819 (inodiftagene vixteplasmid) in patients with NMIBC adequately treated with Bacillus Calmette-Guerin (BCG) whose…
- Trial name
- NCT03719300
- Testing
- inodiftagene vixteplasmid
- Where
- 48 sites in United States
- Volunteers
- 32 people
- Sponsor
- Anchiano Therapeutics Israel Ltd.
Distal Urethral Cancer, Proximal Urethral Cancer
Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer
The purpose of this research study is to find out what effects, good and/or bad, dose-dense (every 14 days) chemotherapy with gemcitabine (gemcitabine hydrochloride) and cisplatin given before surgery have on patients and their…
- Conditions
- Distal Urethral Cancer, Proximal Urethral Cancer, Squamous Cell Carcinoma of the Bladder, Stage II Bladder Cancer
- Trial name
- NCT01611662
- Testing
- gemcitabine hydrochloride, cisplatin, therapeutic conventional surgery
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Fox Chase Cancer Center
Bladder Cancer
Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
This Phase Ib/II study is designed to assess the safety, tolerability, pharmacokinetics, immunogenicity, patient reported outcomes (PROs), and preliminary anti-tumor activity of atezolizumab administered by intravenous (IV)…
- Trial name
- NCT02792192
- Testing
- Atezolizumab, Bacille Calmette-Guérin
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Non-muscle Invasive Bladder Cancer (NMIBC)
Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer
Purpose of this study is to determine appropriate dosing of ABI-009 and evaluate the safety and anti-tumor activity of ABI-009 in treatment of non-muscle invasive bladder cancer
- Trial name
- NCT02009332
- Testing
- ABI-009, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Aadi Bioscience, Inc.
Muscle-invasive Urothelial Cancer of the Bladder
Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder
This trial is to assess the efficacy of pembrolizumab (MK3475) added to concurrent radiation and gemcitabine in the management of patients with muscle-invasive urothelial cancer who are not candidates for or decline radical…
- Trial name
- NCT02621151
- Testing
- Pembrolizumab, Transurethral Resection of Bladder Tumor, Gemcitabine
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- NYU Langone Health
Bladder Cancer, Urothelial Carcinoma
Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)
This study aims to demonstrate that home instillation of UGN-102 is a feasible alternative to instillation in a clinical setting, which might mitigate patient challenges (logistical, expense, and comfort) when receiving treatment…
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
- Trial name
- NCT05136898
- Testing
- UGN-102
- Where
- 5 sites in United States
- Volunteers
- 8 people
- Sponsor
- UroGen Pharma Ltd.
Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer
This phase II trial studies the side effects of avelumab and how well it works in combination with fluorouracil and mitomycin or cisplatin and radiation therapy in treating participants with muscle-invasive bladder cancer.
- Conditions
- Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8, Stage II Renal Pelvis Cancer AJCC v8, Stage II Ureter Cancer AJCC v8
- Trial name
- NCT03617913
- Testing
- Avelumab, Cisplatin, Fluorouracil
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Mayo Clinic
Bladder Cancer, Metastatic Bladder Cancer
A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer
This is a pilot study of avelumab in patients with non-metastatic, muscle invasive bladder cancer who are eligible for radical cystectomy (RC), but are ineligible for cisplatin based neoadjuvant therapy.
- Conditions
- Bladder Cancer, Metastatic Bladder Cancer, Invasive Bladder Cancer
- Trial name
- NCT03498196
- Testing
- Avelumab
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- Baylor College of Medicine